Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Helinorm
- Development stage
- Unknown
- Lead developer
- Nizhpharm
- Modality
- Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
Helinorm is a metabiotic dietary supplement developed by MG Lifecare for the eradication of *Helicobacter pylori* and the management of associated gastrointestinal conditions such as gastric ulcers and gastritis. The active ingredient is Pylopass, which consists of inactivated cells of the probiotic strain *Limosilactobacillus reuteri* (formerly *Lactobacillus reuteri*) DSMZ17648. Unlike traditional live probiotics, this metabiotic functions through a physical mechanism of action where the inactivated bacterial cells specifically recognize and bind to surface receptors on the *H. pylori* cell wall. This binding forms coaggregates that are subsequently flushed out of the gastrointestinal tract through natural excretion, effectively reducing the *H. pylori* bacterial load without disrupting the commensal gut microbiota.
- Brand names
- HelinormGo Away H.Pylori
- Other names
- PylopassLimosilactobacillus reuteri DSMZ17648Lactobacillus reuteri DSMZ17648
Beyond the preview
Go deeper on Helinorm.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Helinorm.